SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment

Bibliography

• Papers of special note have been highlighted as either of interest (*) or of considerable interest (**) to readers.
   Google Scholar

• Tahrani AA, Barnett AH, Bailey CJ. SGLT inhibitors in management of diabetes. Lancet Diabetes Endocrinol. 2013;1:140–151.
   PubMed Web of Science ®Google Scholar
• Hasan FM, Alsahli M, Gerich JE. SGLT2 inhibitors in the treatment of type 2 diabetes. Diabetes Res Clin Pract. 2014;104:297–322.
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci. 2011;32:63–71.
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32:515–531.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Drug-drug interactions with SGLT-2 inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes. Clin Pharmacokinet. 2014;53:295–304.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Clin Pharmacokinet. 2015;54:691–708.
   PubMed Web of Science ®Google Scholar

* Updated review on the efficacy and safety of SGLT2 inhibitors in patients with renal impairment.

• Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–274.
   PubMed Web of Science ®Google Scholar

* Systematic review summarizing the efficacy and safety of SGLT2 inhibitors in type 2 diabetes.

• Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord. 2013;13:58.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59.
   PubMed Web of Science ®Google Scholar

** Updated review summarizing the current knowledge on SGLT2 inhibitors.

• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–149.
   PubMed Web of Science ®Google Scholar

** Updated position statement where SGLT2 inhibitors are positioned in the algorithm of treatment of type 2 diabetes.

• Plosker GL. Canagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74:807–824.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency [Internet]. Assessment report. Canagliflozin. 2013. [cited 2015 Oct 15]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002649/WC500156457.pdf
   Google Scholar
• Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72:2289–2312.
   PubMed Web of Science ®Google Scholar
• Plosker GL. Dapagliflozin: a review of its use in patients with type 2 diabetes. Drugs. 2014;74:2191–2209.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency [Internet]. Assessment report. Forxiga (dapagliflozin). 2012. [cited 2015 Oct 15]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002322/WC500136024.pdf
   Google Scholar
• Scott LJ. Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74:1769–1784.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report: Jardiance [Internet]. International non-proprietary name: empagliflozin. 2014. [cited 2015 Oct 15]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002677/WC500168594.pdf.
   Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015. Epub 2015 Sep 17. DOI:10.1056/NEJMoa1504720.
   PubMed Web of Science ®Google Scholar

** Landmark study demonstrating that empagliflozin markedly reduces cardiovascular and total mortality in patients with type 2 diabetes and cardiovascular disease, with a good safety profile.

• Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335–1380.
   PubMed Web of Science ®Google Scholar

* Exhaustive review on SGLT2 inhibitors for treating type 2 diabetes, including new agents in development.

• Rieg T, Masuda T, Gerasimova M, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol. 2014;306:F188–93.
   PubMed Web of Science ®Google Scholar
• Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36:2154–2161.
   PubMed Web of Science ®Google Scholar
• Sha S, Polidori D, Farrell K, et al. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study. Diabetes Obes Metab. 2015;17:188–197.
   PubMed Web of Science ®Google Scholar
• Polidori D, Mari A, Ferrannini E. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes. Diabetologia. 2014;57:891–901.
   PubMed Web of Science ®Google Scholar
• Elkinson S, Scott LJ. Canagliflozin: first global approval. Drugs. 2013;73:979–988.
   PubMed Web of Science ®Google Scholar
• Lamos EM, Younk LM, Davis SN. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013;9:763–775.
   PubMed Web of Science ®Google Scholar
• Yang XP, Lai D, Zhong XY, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol. 2014;70:1149–1158.
   PubMed Web of Science ®Google Scholar
• Bode B, Stenlof K, Harris S, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. Diabetes Obes Metab. 2015;17:294–303.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Chuck L, González-Ortiz M, et al. Initial combination therapy with canagliflozin (CANA) plus metformin extended-release (MET XR) in drug-naïve type 2 diabetes mellitus (T2DM). Abstract presented at the annual meeting of the American Diabetes Association; 2015 June; Boston. LB DIA3011 abstract 2015.
   Google Scholar
• Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941–950.
   PubMed Web of Science ®Google Scholar
• Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582–2592.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013;36:2508–2515.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38:355–364.
   PubMed Web of Science ®Google Scholar
• Bailey RA, Damaraju CV, Martin SC, et al. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin. Am J Manag Care. 2014;20:S16–24.
   PubMed Web of Science ®Google Scholar
• Merovci A, Mari A, Solis C, et al. Dapagliflozin lowers plasma glucose concentration and improves beta-cell function. J Clin Endocrinol Metab. 2015;100:1927–1932.
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Paquot N. Metabolic effects SGLT2 inhibitors beyond increased glucosuria: a review of clinical evidence. Diabetes Metab. 2014;40:S4–S11.
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Lacreta F, et al. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014;53:17–27.
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43.
   PubMed Web of Science ®Google Scholar
• Bolinder J, Ljunggren O, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16:159–169.
   PubMed Web of Science ®Google Scholar
• Wilding JP, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16:124–136.
   PubMed Web of Science ®Google Scholar
• Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44:375–393.
   PubMed Web of Science ®Google Scholar
• Sun YN, Zhou Y, Chen X, et al. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials. BMJ Open. 2014 4:e004619. doi:10.1136/bmjopen-2013-004619.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang L, Wu B, et al. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014;30:204–221.
   PubMed Web of Science ®Google Scholar
• List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650–657.
   PubMed Web of Science ®Google Scholar
• Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66:446–456.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015–2022.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Del Prato S, Duran-Garcia S, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 2014;16:1111–1120.
   PubMed Web of Science ®Google Scholar
• Del Prato S, Nauck M, Duran-Garcia S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab. 2015;17:581–590.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376–383.
   PubMed Web of Science ®Google Scholar
• Goring S, Hawkins N, Wygant G, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab. 2014;16:433–442.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet. 2014;53:213–225.
   PubMed Web of Science ®Google Scholar
• Seman L, Macha S, Nehmiz G, et al. Empagliflozin (BI 10773), a potent and selective SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Drug Dev. 2013;2:152–161.
   PubMed Web of Science ®Google Scholar
• Merker L, Haring HU, Christiansen AV, et al. Empagliflozin as add-on to metformin in people with Type 2 diabetes. Diabet Med. 2015. doi:10.1111/dme.12814.
   PubMedGoogle Scholar
• Kovacs CS, Seshiah V, Merker L, et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin Ther. 2015;37:1773–1788.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17:936–948.
   PubMed Web of Science ®Google Scholar
• Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16:984–993.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Seman L, Seewaldt-Becker E, et al. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:721–728.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Berk A, Hantel S, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013;36:4015–4021.
   PubMed Web of Science ®Google Scholar
• Ridderstrale M, Andersen KR, Zeller C, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:691–700.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Seman LJ, Jelaska A, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15:1154–1160.
   PubMed Web of Science ®Google Scholar
• Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a randomised, 24-week, double-blind, placebo-controlled, parallel group, trial with sitagliptin as active comparator. Lancet Diabetes Endocrinol. 2013;1:208–219.
   PubMed Web of Science ®Google Scholar
• Lewin A, DeFronzo RA, Patel S, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015;38:394–402.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384–393.
   PubMed Web of Science ®Google Scholar
• Barnett AH. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med. 2013;125:92–100.
   PubMed Web of Science ®Google Scholar

* Overview on the impact of SGLT2 inhibitors on body weight as add-on value to the glucose-lowering effect.

• Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:911–922.
   PubMed Web of Science ®Google Scholar
• Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015;38:1161–1172.
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Stenlof K, Leiter LA, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58:1183–1187.
   PubMed Web of Science ®Google Scholar
• Traina S, Guthrie R, Slee A. The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes. Postgrad Med. 2014;126:7–15.
   PubMed Web of Science ®Google Scholar
• Lambers Heerspink HJ, De Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853–862.
   PubMed Web of Science ®Google Scholar
• Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020–1031.
   PubMed Web of Science ®Google Scholar
• Sjostrom CD, Hashemi M, Sugg J, et al. Dapagliflozin-induced weight loss affects 24-week glycated haemoglobin and blood pressure levels. Diabetes Obes Metab. 2015;17:809–812.
   PubMed Web of Science ®Google Scholar
• Grandy S, Hashemi M, Langkilde AM, et al. Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab. 2014;16:645–650.
   PubMed Web of Science ®Google Scholar
• Neeland I, McGuire DK, Chilton RJ, et al. The sodium glucose co-transporter 2 inhibitor (SGLT2i) empagliflozin reduces weight and markers of visceral adiposity (VA) in type 2 diabetes (T2D) in short- and intermediate term [abstract]. Circulation. 2014;130: 16518.
   Google Scholar
• Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium glucose cotransporter 2 (SGLT2) inhibition. Diabetes Care. 2015;38:1730–1735.
   PubMed Web of Science ®Google Scholar
• Perkins BA, Cherney DZ, Partridge H, et al. Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37:1480–1483.
   PubMed Web of Science ®Google Scholar
• Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014;8:330–339.
   PubMed Web of Science ®Google Scholar
• Maliha G, Townsend RR. SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens. 2015;9:48–53.
   PubMed Web of Science ®Google Scholar

* Overview on the impact of SGLT2 inhibitors on arterial blood pressure as add-on value to the glucose-lowering effect.

• Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8:262–75 e9.
   PubMed Web of Science ®Google Scholar
• Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16:1087–1095.
   PubMed Web of Science ®Google Scholar
• Sjostrom CD, Johansson P, Ptaszynska A, et al. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diab Vasc Dis Res. 2015;12:352–358.
   PubMed Web of Science ®Google Scholar
• Engeli S, Jordan J. Novel metabolic drugs and blood pressure: implications for the treatment of obese hypertensive patients? Curr Hypertens Rep. 2013;15:470–474.
   PubMed Web of Science ®Google Scholar
• Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420–428.
   PubMed Web of Science ®Google Scholar
• Geerlings S, Fonseca V, Castro-Diaz D, et al. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103:373–381.
   PubMed Web of Science ®Google Scholar
• Nicolle LE, Capuano G, Ways K, et al. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin. 2012;28:1167–1171.
   PubMed Web of Science ®Google Scholar
• Mikhail N. Safety of canagliflozin in patients with type 2 diabetes. Curr Drug Saf. 2014;9:127–132.
   PubMedGoogle Scholar
• Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:473–478.
   PubMed Web of Science ®Google Scholar
• Ptaszynska A, Johnsson KM, Parikh SJ, et al. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events. Drug Saf. 2014;37:815–829.
   PubMed Web of Science ®Google Scholar
• Nyirjesy P, Zhao Y, Ways K, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28:1173–1178.
   PubMed Web of Science ®Google Scholar
• Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014;30:1109–1119.
   PubMed Web of Science ®Google Scholar
• Johnsson KM, Ptaszynska A, Schmitz B, et al. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27:479–484.
   PubMed Web of Science ®Google Scholar
• Weir MR, Kline I, Xie J, et al. Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR). Curr Med Res Opin. 2014;30:1759–1768.
   PubMed Web of Science ®Google Scholar
• Vallon V, Thomson SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol. 2012;74:351–375.
   PubMed Web of Science ®Google Scholar
• De Nicola L, Gabbai FB, Liberti ME, et al. Sodium/Glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis. 2014;64:16–24.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Drug safety communications: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [Internet]. 2015. [cited 2015 Oct 15]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf
   Google Scholar
• Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687–1693.
   PubMed Web of Science ®Google Scholar
• Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124:509–514.
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014;124:499–508.
   PubMed Web of Science ®Google Scholar
• Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512–517.
   PubMed Web of Science ®Google Scholar
• Taylor SI, Blau JE, Rother KI. Perspective: SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849–2852.
   PubMed Web of Science ®Google Scholar

* Discussion about the recent warning after the report of cases of euglycemic ketoacidosis in patients treated with SGLT2 inhibitors.

• Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38:1680–1686.
   PubMed Web of Science ®Google Scholar
• Ptaszynska A, Hardy E, Johnsson E, et al. Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med. 2013;125:181–189.
   PubMed Web of Science ®Google Scholar
• Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos. 2014;35:391–404.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Trujillo A, Vijapurkar U, et al. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:426–429.
   PubMed Web of Science ®Google Scholar
• Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3:8–10.
   PubMed Web of Science ®Google Scholar
• Ljunggren O, Bolinder J, Johansson L, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14:990–999.
   PubMed Web of Science ®Google Scholar
• Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–971.
   PubMed Web of Science ®Google Scholar
• Lin HW, Tseng CH. A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol. 2014;2014:719578.
   PubMed Web of Science ®Google Scholar
• Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995).2013;41:72–84.
   Google Scholar
• Sinclair A, Bode B, Harris S, et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord. 2014;14:37.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Cefalu WT, De Bruin TW, et al. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014;62:1252–1262.
   PubMed Web of Science ®Google Scholar
• Elmore LK, Baggett S, Kyle JA, et al. A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes. Consult Pharm. 2014;29:335–346.
   PubMedGoogle Scholar
• Mikhail N. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus. South Med J. 2015;108:91–96.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol. 2014;10:647–663.
   PubMed Web of Science ®Google Scholar
• Kasichayanula S, Liu X, Pe Benito M, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013;76:432–444.
   PubMed Web of Science ®Google Scholar
• Macha S, Mattheus M, Halabi A, et al. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Diabetes Obes Metab. 2014;16:215–222.
   PubMed Web of Science ®Google Scholar
• Devineni D, Marbury T, Curtin C, et al. Effects of renal function on canagliflozin (CANA) pharmacokinetics (PK) and pharmacodynamics (PD) in non-diabetic subjects. JASN Abstract Supplement of the American Society of Nephrology (ASN) Kidney Week; 2012 October 30 – November 4; San Diego (CA); 2012. Abstract# PUB295.
   Google Scholar
• Food and Drug Administration. Center for drug evaluation and research report [Internet]. Canagliflozin (Invokana). 2013. [cited 2015 Oct 15]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000ClinPharmR.pdf
   Google Scholar
• Ferrannini E, Veltkamp SA, Smulders RA, et al. Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2013;36:1260–1265.
   PubMed Web of Science ®Google Scholar
• Yamout H, Perkovic V, Davies M, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014;40:64–74.
   PubMed Web of Science ®Google Scholar
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463–473.
   PubMed Web of Science ®Google Scholar
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab. 2014;16:1016–1027.
   PubMed Web of Science ®Google Scholar
• Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369–384.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol. 2013;9:529–550.
   PubMed Web of Science ®Google Scholar
• Basile JN. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications. 2013;27:280–286.
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter LA, De Bruin TW, et al. Dapagliflozin’s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care. 2015;38:1218–1227.
   PubMed Web of Science ®Google Scholar
• Foote C, Perkovic V, Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res. 2012;9:117–123.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, De Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) : a randomized placebo-controlled trial. Am Heart J. 2013;166:217–23 e11.
   PubMed Web of Science ®Google Scholar
• Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol. 2014;13:102.
   PubMed Web of Science ®Google Scholar
• Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38:412–419.
   PubMed Web of Science ®Google Scholar
• Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015;17:928–935.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. SGLT2 versus DPP4 inhibitors for type 2 diabetes. Lancet Diabetes Endocrinol. 2013;1:168–170.
   PubMed Web of Science ®Google Scholar
• Bell DS. The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss. Am J Case Rep. 2014;15:152–154.
   PubMedGoogle Scholar